CYP2C19 loss-of-function carriers have increased risk of cardiac, but not limb, events following clopidogrel treatment for peripheral artery disease revascularization
CYP2C19 loss-of-function carriers have increased risk of cardiac, but not limb, events following clopidogrel treatment for peripheral artery disease revascularization. // JVS-Vascular Insights. – URL: https://www.sciencedirect.com/science/article/pii/S2949912726001777?dgcid=rss_sd_all
CYP2C19 loss-of-function carriers have increased risk of cardiac, but not limb, events following clopidogrel treatment for peripheral artery disease revascularization. JVS-Vascular Insights. https://www.sciencedirect.com/science/article/pii/S2949912726001777?dgcid=rss_sd_all
“CYP2C19 loss-of-function carriers have increased risk of cardiac, but not limb, events following clopidogrel treatment for peripheral artery disease revascularization.” JVS-Vascular Insights.
@article{article99023,
title = {CYP2C19 loss-of-function carriers have increased risk of cardiac, but not limb, events following clopidogrel treatment for peripheral artery disease revascularization},
journal = {JVS-Vascular Insights},
url = {https://www.sciencedirect.com/science/article/pii/S2949912726001777?dgcid=rss_sd_all}
}